Go back

Pharma chief says Brexit would seriously disrupt UK bioscience

The need to redraft regulations in the event of a British exit from the European Union would negatively affect patents and patient access to medicines, the chief executive of the Bioindustry Association has said.

Speaking at a House of Lords Science and Technology Committee evidence session on 26 January, Steve Bates said that Brexit would cause major disruption to UK bioscience R&D and would undo the work of “a generation” of legislators who have created an integrated regulatory environment.

He said that part of the success of the growing UK biosciences sector was thanks to the country’s membership of the EU, which he described as the single biggest market for pharmaceuticals.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.